Cargando…
Genetic engineering of pharmacologically regulated T cells, specific for breast cancer target antigens
Autores principales: | Wilkie, S, Burbridge, S, Davies, DM, Chiapero-Stanke, L, Foster, J, Mather, SJ, Maher, J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875613/ http://dx.doi.org/10.1186/bcr2548 |
Ejemplares similares
-
Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes
por: Wilkie, S, et al.
Publicado: (2008) -
Development of breast cancer immunotherapy using MUC1 retargeted T lymphocytes
por: Wilkie, S, et al.
Publicado: (2006) -
Development of HER2-specific chimeric antigen receptor T cells for the treatment of breast-to-brain metastasis
por: Priceman, Saul, et al.
Publicado: (2015) -
Antigen-specific T cell redirectors (ATR) for antigen-specific redirection of T cells to tumors
por: Schütz, Christian, et al.
Publicado: (2014) -
Living with genetic risk of breast cancer: what have we learned?
por: Foster, C
Publicado: (2008)